apixaban and dabigatran

Pharmacodynamic interaction: additive anticoagulant effects. Apixaban inhibits factor Xa, and dabigatran directly inhibits thrombin (factor IIa). Both actions occur in the coagulation cascade, and their concurrent use produces a synergistic increase in anticoagulant activity, markedly suppressing clot formation.

Concurrent use of apixaban and dabigatran significantly increases the risk of major bleeding, including intracranial haemorrhage, gastrointestinal bleeding, and other life-threatening haemorrhagic events. The risk of bleeding is additive and substantially higher than with either agent alone.

Do not co-prescribe apixaban and dabigatran. When switching therapy from one to the other, follow established switching guidelines: stop the first anticoagulant and start the second at the time of the next scheduled dose, taking renal function into account. Alternatives should be considered if temporary anticoagulation is needed for procedures or events.

Combined use is not studied in clinical trials due to the unacceptable bleeding risk. The interaction is well established from pharmacodynamic principles and reports of significant haemorrhage when overlapping or combining anticoagulants. Guidelines for switching between direct oral anticoagulants emphasise avoiding overlap.